DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 12,841 shares of the medical device company’s stock after acquiring an additional 1,740 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in DexCom were worth $861,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Canada Pension Plan Investment Board lifted its position in shares of DexCom by 189.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after buying an additional 435,401 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in DexCom by 53.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock worth $66,352,000 after purchasing an additional 345,114 shares in the last quarter. Bellevue Group AG grew its position in DexCom by 33.5% during the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock worth $169,380,000 after purchasing an additional 306,604 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new stake in DexCom during the 2nd quarter valued at $31,793,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

DexCom stock opened at $75.88 on Friday. The firm has a market capitalization of $29.64 billion, a P/E ratio of 45.44, a PEG ratio of 2.22 and a beta of 1.17. The business has a 50-day moving average of $69.89 and a 200-day moving average of $92.01. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on DXCM shares. Royal Bank of Canada dropped their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Barclays lowered their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. Baird R W cut DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Oppenheimer decreased their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, BTIG Research decreased their target price on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.